HGG-15. PHASE 2 NESTED COHORT STUDY OF DEPATUXIZUMAB MAFODOTIN IN CHILDREN WITH HIGH GRADE GLIOMA AND DIFFUSE INTRINSIC PONTINE GLIOMA WITH EGFR AMPLIFICATION

摘要

INTRODUCTIONPediatric high grade gliomas (HGGs) and diffuse intrinsic pontine gliomas have no adequate therapy and are almost universally fatal. Depatuxizumab mafodotin (depatux-m) is an antibody-drug conjugate, comprised of anti-EGFR antibody linked to a microtubule cytotoxin, monomethyl auristatin F, that has demonstrated promising antitumor activity in patients with EGFR gene-amplified tumors in two studies of adult glioblastoma. While EGFR amplification occurs in ~50% of adult glioblastomas, it occurs in only 1-3% of children. Due to this rarity, a nested pediatric cohort has been designed within the adult depatux-m phase 2 study in recurrent glioblastoma ().